Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis
Eur Respir J
.
2020 Jun 4;55(6):2000038.
doi: 10.1183/13993003.00038-2020.
Print 2020 Jun.
Authors
Melissa Y Y Moey
1
,
Paul Gougis
2
,
Vincent Goldschmidt
2
,
Douglas B Johnson
3
,
Bénédicte Lebrun-Vignes
2
3
,
Javid Moslehi
4
,
Jacques Cadranel
5
,
Joe-Elie Salem
2
4
Affiliations
1
Dept of Cardiovascular Sciences, Vidant Medical Center/East Carolina University, Greenville, NC, USA.
2
Dept of Pharmacology, INSERM CIC-1901, UNICO-GRECO Cardio-oncology Program, CLIP2 Galilée, APHP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.
3
Pitié and Saint Antoine Pharmacovigilance Centres, APHP, Sorbonne Université, UPEC EA EpiDermE 7379, Paris, France.
4
Dept of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
5
Chest Dept, Thoracic Oncology Expert Center, Rare Pulmonary Diseases Constitutive Center, GRC #4, Theranoscan Sorbonne Université and APHP, Sorbonne Université, Hôpital Tenon, Paris, France jacques.cadranel@aphp.fr.
PMID:
32079644
DOI:
10.1183/13993003.00038-2020
No abstract available
Publication types
Letter
MeSH terms
Data Management
Humans
Immune Checkpoint Inhibitors*
Pharmacovigilance
Pneumonia* / chemically induced
World Health Organization
Substances
Immune Checkpoint Inhibitors